NRC HEALTH
For the period ended Sep 30, 2026. Filed Nov 4, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 4, 2026
NRC$26.67+3.1%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Shareholders’ Equity
(In thousands except share and per share amounts, unaudited)
| Common Stock | Additional Paid-in Capital | Retained Earnings (Deficit) | Treasury Stock | Total | |
|---|---|---|---|---|---|
| Balances at December 31, 2025 | $32 | $183,880 | $(17,298) | $(152,624) | $13,990 |
| Purchase of 109,701 shares treasury stock | - | - | - | (1,858) | (1,858) |
| Issuance of 9,145 shares of common stock for the exercise of stock options | - | 139 | - | - | 139 |
| Non-cash stock compensation expense | - | 1,608 | - | - | 1,608 |
| Dividends declared of $0.16 per share of common stock | - | - | (3,606) | - | (3,606) |
| Net income | - | - | 3,222 | - | 3,222 |
| Balances at March 31, 2026 | $32 | $185,627 | $(17,682) | $(154,482) | $13,495 |
| Purchase of 397,381 shares treasury stock | - | - | - | (7,492) | (7,492) |
| Non-cash stock compensation expense | - | 7,371 | - | - | 7,371 |
| Dividends declared of $0.16 per share of common stock | - | - | (3,542) | - | (3,542) |
| Net loss | - | - | (3,283) | - | (3,283) |
| Balances at June 30, 2026 | $32 | $192,998 | $(24,507) | $(161,974) | $6,549 |
| Purchase of 788,777 shares treasury stock | - | - | - | (16,835) | (16,835) |
| Non-cash stock compensation expense | - | (134) | - | - | (134) |
| Dividends declared of $0.16 per share of common stock | - | - | (3,406) | - | (3,406) |
| Net income | - | - | 4,704 | - | 4,704 |
| Balances at September 30, 2026 | $32 | $192,864 | $(23,209) | $(178,809) | $(9,122) |
CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS’** EQUITY**
(In thousands except share and per share amounts, unaudited)
| Common Stock | Additional Paid-in Capital | Retained Earnings (Deficit) | Treasury Stock | Total | |
|---|---|---|---|---|---|
| Balances at December 31, 2024 | $31 | $180,249 | $(17,064) | $(131,932) | $31,284 |
| Purchase of 307,709 shares treasury stock | - | - | - | (4,967) | (4,967) |
| Issuance of 10,014 shares of common stock for the exercise of stock options | - | 132 | - | - | 132 |
| Non-cash stock compensation expense | - | 171 | - | - | 171 |
| Dividends declared of $0.12 per share of common stock | - | - | (2,735) | - | (2,735) |
| Net income | - | - | 5,787 | - | 5,787 |
| Balances at March 31, 2025 | $31 | $180,552 | $(14,012) | $(136,899) | $29,672 |
| Purchase of 381,736 shares treasury stock | - | - | - | (5,769) | (5,769) |
| Issuance of 700,000 shares of nonvested stock | 1 | (1) | - | - | - |
| Non-cash stock compensation expense | - | 307 | - | - | 307 |
| Dividends declared of $0.12 per share of common stock | - | - | (2,776) | - | (2,776) |
| Net loss | - | - | (106) | - | (106) |
| Balances at June 30, 2025 | $32 | $180,858 | $(16,894) | $(142,668) | $21,328 |
| Purchase of 618,264 shares treasury stock | - | - | - | (9,363) | (9,363) |
| Issuance of 172,000 shares of nonvested stock | - | - | - | - | - |
| Non-cash stock compensation expense | - | 925 | - | - | 925 |
| Dividends declared of $0.12 per share of common stock | - | - | (2,698) | - | (2,698) |
| Net income | - | - | 4,122 | - | 4,122 |
| Balances at September 30, 2025 | $32 | $181,783 | $(15,470) | $(152,031) | $14,314 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.